Dyne Therapeutics (NASDAQ:DYN) Shares Down 3%

Dyne Therapeutics, Inc. (NASDAQ:DYN) fell 3% during trading on Tuesday . The stock traded as low as $33.42 and last traded at $33.60. 84,112 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 1,598,878 shares. The stock had previously closed at $34.63.

Analysts Set New Price Targets

DYN has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday. Oppenheimer restated an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Guggenheim boosted their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Finally, JPMorgan Chase & Co. boosted their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Stock Performance

The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -8.72 and a beta of 1.07. The business’s 50 day moving average is $40.89 and its 200 day moving average is $33.71.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. Research analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now directly owns 131,636 shares of the company’s stock, valued at approximately $4,529,594.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares in the company, valued at approximately $4,529,594.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares in the company, valued at $3,405,524.40. The disclosure for this sale can be found here. Insiders have sold a total of 12,705 shares of company stock worth $437,701 in the last three months. Insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its stake in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares in the last quarter. Amalgamated Bank grew its position in Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after purchasing an additional 796 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Dyne Therapeutics during the 2nd quarter valued at about $203,000. Finally, Farallon Capital Management LLC purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at about $212,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.